Back to top

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus ...

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeyondSpring Inc. (BYSI)